Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) – Pipeline Review, H2 2016’, provides in depth analysis on Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted pipeline therapeutics.

The report provides comprehensive information on the Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2)

The report reviews Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

The report assesses Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC 2.7.10.2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Aerie Pharmaceuticals, Inc.

Aptose Biosciences Inc.

Astex Pharmaceuticals, Inc.

AstraZeneca Plc

Bristol-Myers Squibb Company

Celon Pharma Sp. z o.o.

Concert Pharmaceuticals, Inc.

CTI BioPharma Corp.

Daiichi Sankyo Company, Limited

Eli Lilly and Company

Genentech, Inc.

Gilead Sciences, Inc.

Incyte Corporation

Merck & Co., Inc.

Nerviano Medical Sciences S.r.l.

Nippon Shinyaku Co., Ltd.

Novartis AG

SOM Innovation Biotech SL

Theravance Biopharma, Inc.

Tolero Pharmaceuticals, Inc.

Tragara Pharmaceuticals, Inc.

Vectura Group Plc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC

2.7.10.2) Overview 10

Therapeutics Development 11

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC

2.7.10.2) - Products under Development by Stage of Development 11

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC

2.7.10.2) - Products under Development by Therapy Area 12

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC

2.7.10.2) - Products under Development by Indication 13

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC

2.7.10.2) - Pipeline Products Glance 15

Late Stage Products 15

Early Stage Products 16

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC

2.7.10.2) - Products under Development by Companies 17

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC

2.7.10.2) - Products under Development by Universities/Institutes 22

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC

2.7.10.2) - Therapeutics Assessment 24

Assessment by Monotherapy/Combination Products 24

Assessment by Mechanism of Action 25

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC

2.7.10.2) - Companies Involved in Therapeutics Development 29

Aerie Pharmaceuticals, Inc. 29

Aptose Biosciences Inc. 30

Astex Pharmaceuticals, Inc. 31

AstraZeneca Plc 32

Bristol-Myers Squibb Company 33

Celon Pharma Sp. z o.o. 34

Concert Pharmaceuticals, Inc. 35

CTI BioPharma Corp. 36

Daiichi Sankyo Company, Limited 37

Eli Lilly and Company 38

Genentech, Inc. 39

Gilead Sciences, Inc. 40

Incyte Corporation 41

Merck & Co., Inc. 42

Nerviano Medical Sciences S.r.l. 43

Nippon Shinyaku Co., Ltd. 44

Novartis AG 45

SOM Innovation Biotech SL 46

Theravance Biopharma, Inc. 47

Tolero Pharmaceuticals, Inc. 48

Tragara Pharmaceuticals, Inc. 49

Vectura Group Plc 50

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC

2.7.10.2) - Drug Profiles 51

AC-410 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

AR-13154 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

AT-9283 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

AZD-1480 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

baricitinib - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

BVB-808 - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

CHZ-868 - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

CPL-407105 - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

CPL-40722 - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

CTP-543 - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

lestaurtinib - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

MA-2014 - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

momelotinib dihydrochloride - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

MRLB-11055 - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

NMSP-113 - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

NMSP-953 - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

NS-018 - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

pacritinib - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

ruxolitinib phosphate - Drug Profile 91

Product Description 91

Mechanism Of Action 91

R&D Progress 91

SAR-317461 - Drug Profile 104

Product Description 104

Mechanism Of Action 104

R&D Progress 104

Small Molecule to Inhibit JAK2 for Leukemia - Drug Profile 105

Product Description 105

Mechanism Of Action 105

R&D Progress 105

Small Molecules to Inhibit JAK2 for Cancer - Drug Profile 106

Product Description 106

Mechanism Of Action 106

R&D Progress 106

Small Molecules to Inhibit JAK2 for Myeloproliferative Disorders - Drug Profile 107

Product Description 107

Mechanism Of Action 107

R&D Progress 107

Small Molecules to Inhibit JAK2 for Myeloproliferative Disorders - Drug Profile 108

Product Description 108

Mechanism Of Action 108

R&D Progress 108

Small Molecules to Inhibit JAK2 for Myeloproliferative Neoplasms - Drug Profile 109

Product Description 109

Mechanism Of Action 109

R&D Progress 109

TD-1473 - Drug Profile 110

Product Description 110

Mechanism Of Action 110

R&D Progress 110

TG-02 - Drug Profile 111

Product Description 111

Mechanism Of Action 111

R&D Progress 111

TP-0413 - Drug Profile 114

Product Description 114

Mechanism Of Action 114

R&D Progress 114

VR-588 - Drug Profile 115

Product Description 115

Mechanism Of Action 115

R&D Progress 115

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC

2.7.10.2) - Dormant Projects 116

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC

2.7.10.2) - Discontinued Products 122

Tyrosine Protein Kinase JAK2 (Janus Kinase 2 or JAK2 or EC

2.7.10.2) - Featured News & Press Releases 124

Jun 23, 2016: FDA Grants Breakthrough Therapy Designation for Incyte’s Ruxolitinib (Jakafi) in Acute Graft-Versus-Host Disease (GVHD) 124

Jun 10, 2016: New Phase 3 Data Show Jakafi (ruxolitinib) is Superior to Best Available Therapy in Patients with Polycythemia Vera 124

Jun 09, 2016: Baricitinib Significantly Reduces Joint Damage Progression In Rheumatoid Arthritis In Patients Who Do Not Respond To Conventional DMARDs 125

Jun 09, 2016: Patient-reported outcomes across phase 3 studies of baricitinib demonstrate statistically significant improvements in physical function and quality of life symptoms in patients with rheumatoid arthritis (RA) 126

Jun 09, 2016: Theravance Biopharma Reports Positive Results From Phase 1 Clinical Trial of TD-1473, a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor 128

Jun 07, 2016: Long-Term Follow Up Data For Pacritinib Presented At 2016 ASCO Annual Meeting 129

Jun 07, 2016: Results Of Clinical And Patient-Reported Outcomes Data For Baricitinib In Patients With Rheumatoid Arthritis To Be Presented At Annual European Congress Of Rheumatology 133

Jun 06, 2016: Five-year Results from Phase 3 Study of Jakafi (ruxolitinib) Show Sustained Overall Survival Benefit in Patients with Myelofibrosis 134

May 19, 2016: CTI BioPharma Announces Presentations At The American Society Of Clinical Oncology Annual Meeting 135

May 19, 2016: Incyte Highlights Jakafi (ruxolitinib) Abstract to be Presented at the 2016 ASCO and EHA Annual Meetings 136

May 19, 2016: Concert Pharmaceuticals Initiates Phase 1 Trial of CTP-543 as a New Treatment for Alopecia Areata 137

May 04, 2016: Concert Pharmaceuticals Unveils CTP-543 for Treatment of Alopecia Areata 138

May 03, 2016: Parkinson's disease pathogenesis reduced in rat model by a cell-signaling inhibitor drug 138

Apr 20, 2016: Preclinical Data Presented At AACR Indicate Pacritinib Potential To Eradicate Therapy-Resistant Leukemia Stem Cells Residing In Bone Marrow Microenvironment 140

Apr 13, 2016: CTI BioPharma Announces Presentation on pacritinib at the American Association of Cancer Research Annual Meeting 140

Appendix 142

Methodology 142

Coverage 142

Secondary Research 142

Primary Research 142

Expert Panel Validation 142

Contact Us 142

Disclaimer 143

List of Tables

List of Tables

Number of Products under Development for, H2 2016 11

Number of Products under Development by Therapy Area, H2 2016 12

Number of Products under Development by Indication, H2 2016 13

Comparative Analysis by Late Stage Development, H2 2016 15

Comparative Analysis by Early Stage Products, H2 2016 16

Number of Products under Development by Companies, H2 2016 17

Products under Development by Companies, H2 2016 18

Products under Development by Companies, H2 2016 (Contd..1) 19

Products under Development by Companies, H2 2016 (Contd..2) 20

Products under Development by Companies, H2 2016 (Contd..3) 21

Number of Products under Investigation by Universities/Institutes, H2 2016 22

Products under Investigation by Universities/Institutes, H2 2016 23

Assessment by Monotherapy/Combination Products, H2 2016 24

Number of Products by Stage and Mechanism of Action, H2 2016 25

Number of Products by Stage and Route of Administration, H2 2016 27

Number of Products by Stage and Molecule Type, H2 2016 28

Pipeline by Aerie Pharmaceuticals, Inc., H2 2016 29

Pipeline by Aptose Biosciences Inc., H2 2016 30

Pipeline by Astex Pharmaceuticals, Inc., H2 2016 31

Pipeline by AstraZeneca Plc, H2 2016 32

Pipeline by Bristol-Myers Squibb Company, H2 2016 33

Pipeline by Celon Pharma Sp. z o.o., H2 2016 34

Pipeline by Concert Pharmaceuticals, Inc., H2 2016 35

Pipeline by CTI BioPharma Corp., H2 2016 36

Pipeline by Daiichi Sankyo Company, Limited, H2 2016 37

Pipeline by Eli Lilly and Company, H2 2016 38

Pipeline by Genentech, Inc., H2 2016 39

Pipeline by Gilead Sciences, Inc., H2 2016 40

Pipeline by Incyte Corporation, H2 2016 41

Pipeline by Merck & Co., Inc., H2 2016 42

Pipeline by Nerviano Medical Sciences S.r.l., H2 2016 43

Pipeline by Nippon Shinyaku Co., Ltd., H2 2016 44

Pipeline by Novartis AG, H2 2016 45

Pipeline by SOM Innovation Biotech SL, H2 2016 46

Pipeline by Theravance Biopharma, Inc., H2 2016 47

Pipeline by Tolero Pharmaceuticals, Inc., H2 2016 48

Pipeline by Tragara Pharmaceuticals, Inc., H2 2016 49

Pipeline by Vectura Group Plc, H2 2016 50

Dormant Projects, H2 2016 116

Dormant Projects (Contd..1), H2 2016 117

Dormant Projects (Contd..2), H2 2016 118

Dormant Projects (Contd..3), H2 2016 119

Dormant Projects (Contd..4), H2 2016 120

Dormant Projects (Contd..5), H2 2016 121

Discontinued Products, H2 2016 122

Discontinued Products (Contd..1), H2 2016 123

List of Figures

List of Figures

Number of Products under Development for, H2 2016 11

Number of Products under Development by Therapy Area, H2 2016 12

Number of Products under Development by Top 10 Indication, H2 2016 13

Comparative Analysis by Late Stage Development, H2 2016 15

Comparative Analysis by Early Stage Products, H2 2016 16

Assessment by Monotherapy/Combination Products, H2 2016 24

Number of Products by Stage and Mechanism of Actions, H2 2016 25

Number of Products by Routes of Administration, H2 2016 26

Number of Products by Stage and Routes of Administration, H2 2016 26

Number of Products by Stage and Molecule Type, H2 2016 28

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports